Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients

Journal of Trauma and Acute Care Surgery

Volumn 74, Issue 1, 2013, Pages 128-135

  Costantini, Todd W ^a   Min, Emily ^a   Box, Kevin ^a   Tran, Vy ^a   Winfield, Robert D ^a   Fortlage, Dale ^a   Doucet, Jay ^a   Bansal, Vishal ^a   Coimbra, Raul ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

anti Xa; deep venous thrombosis; Lovenox; prophylaxis; VTE

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN;

ADULT; ARM FRACTURE; ARTICLE; BLOOD LEVEL; BLUNT TRAUMA; BRAIN HEMANGIOMA; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; DRUG DOSE INCREASE; FEMALE; HOSPITAL ADMISSION; HUMAN; LEG FRACTURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PATIENT; PELVIS FRACTURE; PHLEBOGRAPHY; PRIORITY JOURNAL; SPINAL CORD INJURY; SPINE FRACTURE; THROMBOSIS PREVENTION; TRAUMA PATIENT; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; ENOXAPARIN; FACTOR XA; FEMALE; HUMANS; MALE; MIDDLE AGED; VENOUS THROMBOEMBOLISM; WOUNDS AND INJURIES;

EID: 84872071115     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0b013e3182788fa7     Document Type: Article

References (28)

1. Pierce CA, Haut ER, Kardooni S, Chang DC, Efron DT, Haider A, Pronovost PJ, Cornwell EE 3rd. Surveillance bias and deep vein thrombosis in the national trauma data bank: the more we look, the more we find. J Trauma. 2008;64:932-936; discussion 936-937.
2. Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA, Hamilton PA. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med. 1996;335:701-707.
3. Knudson MM, Lewis FR, Clinton A, Atkinson K, Megerman J. Prevention of venous thromboembolism in trauma patients. J Trauma. 1994;37: 480-487.
4. Knudson MM, Collins JA, Goodman SB, McCrory DW. Thromboembolism following multiple trauma. J Trauma. 1992;32:2-11.
5. Knudson MM, Morabito D, Paiement GD, Shackleford S. Use of low molecular weight heparin in preventing thromboembolism in trauma patients. J Trauma. 1996;41:446-459.
6. Maung AA, Schuster KM, Kaplan LJ, Maerz LL, Davis KA. Risk of venous thromboembolism after spinal cord injury: not all levels are the same. J Trauma. 2011;71:1241-1245.
7. Knudson MM, Ikossi DG, Khaw L, Morabito D, Speetzen LS. Thromboembolism after trauma: an analysis of 1602 episodes from the American College of Surgeons National Trauma Data Bank. Ann Surg. 2004;240: 490-496; discussion 496-498.
8. Cuschieri J, Freeman B, O'Keefe G, Harbrecht BG, Bankey P, Johnson JL, Minei JP, Sperry J, West M, Nathens A, et al. Inflammation and the host response to injury a large-scale collaborative project: patient-oriented research core standard operating procedure for clinical care X. Guidelines for venous thromboembolism prophylaxis in the trauma patient. J Trauma. 2008;65:944-950.
9. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. N Engl J Med. 1994;331: 1601-1606.
10. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:7S-47S.
11. Iqbal Z, Cohen M. Enoxaparin: a pharmacologic and clinical review. Expert Opin Pharmacother. 2011;12:1157-1170.
12. Sanderink GJ, Guimart CG, Ozoux ML, Jariwala NU, Shukla UA, Boutouyrie BX. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res. 2002;105:225-231.
13. Sanderink GJ, Le Liboux A, Jariwala N, Harding N, Ozoux ML, Shukla U, Montay G, Boutouyrie B, Miro A. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther. 2002;72:308-318.
14. Malinoski D, Jafari F, Ewing T, Ardary C, Conniff H, Baje M, Kong A, Lekawa ME, Dolich MO, Cinat ME, et al. Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. J Trauma. 2010;68:874-880.
15. Van PY, Cho SD, Underwood SJ, Morris MS, Watters JM, Schreiber MA. Thrombelastography versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients. J Trauma. 2009;66: 1509-1515; discussion 1515-1507.
16. Samama MM, Poller L. Contemporary laboratory monitoring of low molecular weight heparins. Clin Lab Med. 1995;15:119-123.
17. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecularweight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother. 2009;43:1064-1083.
18. Lin H, Faraklas I, Cochran A, Saffle J. Enoxaparin and antifactor Xa levels in acute burn patients. J Burn Care Res. 2011;32:1-5.
19. Ludwig KP, Simons HJ, Mone M, Barton RG, Kimball EJ. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients. Ann Pharmacother. 2011;45: 1356-1362.
20. Lin H, Faraklas I, Saffle J, Cochran A. Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients. J Trauma. 2011;71:1557-1561.
21. Selby R, Geerts W, Ofosu FA, Craven S, Dewar L, Phillips A, Szalai JP. Hypercoagulability after trauma: hemostatic changes and relationship to venous thromboembolism. Thromb Res. 2009;124:281-287.
22. Hoyt DB, Coimbra R, Potenza B, Doucet J, Fortlage D, Holingsworth- Fridlund P, Holbrook T. A twelve-year analysis of disease and provider complications on an organized Level I trauma service: as good as it gets? J Trauma. 2003;54:26-36; discussion 36-37.
23. Kim DY, Kobayashi L, Barmparas G, Fortlage D, Curry T, Coimbra R. Venous thromboembolism in the elderly: the result of comorbid conditions or a consequence of injury? J Trauma. 2012;72:1286-1291.
24. Rogers FB, Cipolle MD, Velmahos G, Rozycki G, Luchette FA. Practice management guidelines for the prevention of venous thromboembolism in trauma patients: the EAST practice management guidelines work group. J Trauma. 2002;53:142-164.
25. Haut ER, Schneider EB, Patel A, Streiff MB, Haider AH, Stevens KA, Chang DC, Neal ML, Hoeft C, Nathens AB, et al. Duplex ultrasound screening for deep vein thrombosis in asymptomatic trauma patients: a survey of individual trauma surgeon opinions and current trauma center practices. J Trauma. 2011;70:27-33; discussion 33-34.
26. Samama MM. Laboratory monitoring of unfractionated heparin treatment. Clin Lab Med. 1995;15:109-117.
27. MalinoskiDJ,EwingT, PatelMS,NguyenD, LeT, Cui E,KongA,Dolich M, Barrios C, CinatM, et al. The natural history of upper extremity deep venous thromboses in critically ill surgical and trauma patients: what is the role of anticoagulation? J Trauma. 2011;71:316-321; discussion 321-322.
28. Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M. The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost. 1989;62:940-944.